Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma

医学 多西紫杉醇 卡铂 养生 内科学 新辅助治疗 肿瘤科 外科 化疗 存活率 完全响应 不利影响 胃肠病学 癌症 顺铂 乳腺癌
作者
Guoliang Zhang,Qi Zhu,Teng Ma,C. Weng,Dandan Zhang,Hui Zeng,Tao Wang,Feng Gao,Mi Liu,Rui Wang
出处
期刊:Diseases of The Esophagus [Oxford University Press]
卷期号:37 (4)
标识
DOI:10.1093/dote/doad073
摘要

Summary Herein, we aimed to evaluate the efficacy and safety of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma (OSCC). Fifty-one patients with OSCC, treated from July 2020 to October 2022, were analyzed. Of them, 41 patients underwent surgery 4–8 weeks after undergoing two cycles of camrelizumab (200 mg IV Q3W) combined with docetaxel (75 mg/m2 IV Q3W) and carboplatin (area under the curve = 5–6 IV Q3W). The primary endpoint was the pathological complete response rate. All 51 patients (100%) experienced treatment-related grades 1–2 adverse events, and 2 patients (3.9%) experienced grade 4 events (including elevated alanine transaminase/aspartate transferase levels and Guillain–Barre syndrome). Fifty patients were evaluated for the treatment efficacy. Of them, 13 achieved complete response, and the objective response rate was 74%. Only 41 patients underwent surgical treatment. The pathological complete response rate was 17.1%, the major pathological response rate was 63.4%, and the R0 resection rate was 100%. Approximately 22% of the patients had tumor regression grades 0. Eight patients (19.5%) developed surgery-related complications. The median follow-up time was 18 months (range: 3–29 months). Four patients experienced disease progression, while four died. The median disease-free survival and overall survival were not reached. Camrelizumab combined with docetaxel and carboplatin is an effective and safe neoadjuvant treatment for locally advanced OSCC. This regimen may afford a potential strategy to treat patients with locally advanced OSCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
早起大王发布了新的文献求助10
刚刚
刚刚
俏皮煎饼发布了新的文献求助10
刚刚
2秒前
2秒前
qiming完成签到,获得积分10
2秒前
情怀应助你帅你有理采纳,获得10
3秒前
circet发布了新的文献求助30
4秒前
4秒前
5秒前
6秒前
summer完成签到 ,获得积分10
6秒前
6秒前
7秒前
酸汤鱼发布了新的文献求助10
7秒前
Aspen完成签到,获得积分10
8秒前
www0605发布了新的文献求助10
8秒前
9秒前
llzuo完成签到,获得积分10
10秒前
11秒前
Akim应助鲁新连采纳,获得10
11秒前
烟花应助vincentbioinfo采纳,获得10
11秒前
Lucas应助急急国王采纳,获得10
11秒前
Aspen发布了新的文献求助10
11秒前
阿萨德发布了新的文献求助10
11秒前
哭泣剑封发布了新的文献求助10
11秒前
宁宁宁发布了新的文献求助10
11秒前
忐忑的远山应助名金学南采纳,获得10
12秒前
12秒前
bailing128完成签到,获得积分10
14秒前
清欢发布了新的文献求助10
15秒前
暴躁的夏蓉完成签到 ,获得积分10
16秒前
体贴半仙发布了新的文献求助10
17秒前
18秒前
俏皮煎饼完成签到,获得积分20
18秒前
领导范儿应助芋圆采纳,获得10
19秒前
搜集达人应助sunidea采纳,获得10
19秒前
喜悦芝麻完成签到 ,获得积分10
20秒前
情怀应助每天读顶刊采纳,获得10
21秒前
星xing发布了新的文献求助10
21秒前
高分求助中
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Sport in der Antike 800
De arte gymnastica. The art of gymnastics 600
少脉山油柑叶的化学成分研究 530
Mechanical Methods of the Activation of Chemical Processes 510
Berns Ziesemer - Maos deutscher Topagent: Wie China die Bundesrepublik eroberte 500
Stephen R. Mackinnon - Chen Hansheng: China’s Last Romantic Revolutionary (2023) 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2420414
求助须知:如何正确求助?哪些是违规求助? 2110853
关于积分的说明 5341484
捐赠科研通 1838113
什么是DOI,文献DOI怎么找? 915232
版权声明 561142
科研通“疑难数据库(出版商)”最低求助积分说明 489400